drugset
drugset / Trial / NCT04271488

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

NCT04271488 ↗

Phase 1 Recruiting 18 enrolled Eisai Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.

Timeline

Start
2020-02-27
Primary completion
2026-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject E7090 Small molecule 10 mg Oral
Subject E7090 Small molecule 35 mg Oral

Indications

No indication recorded.